Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1124232 | 1.00 | P4HTM (0.50) | P4HTMRAB9AHCAR2HDAC3HDAC1 | |
| SCHEMBL1124134 | 0.84 | MAP3K7 (0.40) | P4HTMRAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL1124135 | 0.84 | MAP3K7 (0.40) | P4HTMRAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL17078118 | 0.84 | HDAC3 (0.38) | P4HTMHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL17078122 | 0.84 | HDAC3 (0.38) | P4HTMHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL7565555 | 0.81 | P4HTM (0.50) | P4HTMRAB9AHCAR2HDAC3HDAC1 | |
| SCHEMBL7565552 | 0.81 | P4HTM (0.50) | P4HTMRAB9AHCAR2HDAC3HDAC1 | |
| SCHEMBL4419341 | 0.80 | KDM4E (0.50) | HCAR2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL4419344 | 0.80 | KDM4E (0.50) | HCAR2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL454424 | 0.77 | P4HTM (0.58) | P4HTMRAB9AHCAR2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3116862-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| WO-2015135091-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015138220-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20110281869-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | AISSAOUI HAMED (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2282996-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141782-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-11-26 | — | — | WO | disclosed |
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-7115616-B2 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-10-03 | — | — | US | disclosed |
| US-6953803-B1 | 1-[(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)]-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one; enzyme inhibitors of lipoprotein associated phospholipase A2 (Lp-PLA2); atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-10-11 | — | — | US | disclosed |
| EP-1173424-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066566-A1 | PYRIMIDINE COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | P4HTM 2258/4885RAB9A 1803/4885HCAR2 624/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | P4HTM 2258/4885RAB9A 1803/4885HCAR2 624/4885 |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | PREP, CTSZ, PEPD | P4HTM 505/4885RAB9A 2725/4885HCAR2 2996/4885 |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | PREP, CTSZ, PEPD | P4HTM 505/4885RAB9A 2725/4885HCAR2 2996/4885 |
| US-20110281869-A1 | TETRAHYDROISOQUINOLINES AS ANTIMALARIAL AGENTS | QTRT2, RECQL, QTRT1 | P4HTM 1934/4885RAB9A 856/4885HCAR2 2378/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | P4HTM 1077/4885RAB9A 2211/4885HCAR2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.